BARDA joined industry partner Jubilant HollisterStier CMO for a ribbon cutting ceremony and a tour of their high-speed, commercial fill-finish line facility in Spokane, Washington. Filling and finishing vials are the last two steps in the manufacturing process for vaccines and therapeutics. During a pandemic or infectious disease outbreak, it is critical to ensure that the nation has enough domestic capacity to complete those final steps and make vaccines and therapeutics available. This project with Jubilant HollisterStier aims to enable faster production of vaccines in the U.S. when needed and to help bolster preparedness ahead of the next public health emergency. Learn more about how we’re making critical investments to foster and expand domestic pharmaceutical manufacturing: https://ow.ly/zvvY50Rfvsk
Biomedical Advanced Research and Development Authority (BARDA)
Government Administration
Washington, District of Columbia 17,699 followers
This page is no longer active.
About us
Advancing medical countermeasures against public health threats. Part of HHS/ASPR. This page is no longer active. Visit our new page at: https://www.linkedin.com/company/biomedical-advanced-research-and-development-authority-barda/?viewAsMember=true https://medicalcountermeasures.gov
- Website
-
https://medicalcountermeasures.gov/barda/
External link for Biomedical Advanced Research and Development Authority (BARDA)
- Industry
- Government Administration
- Company size
- 201-500 employees
- Headquarters
- Washington, District of Columbia
- Founded
- 2006
Updates
-
There’s another chance to submit to DRIVe’s Agnostic Diagnostics program! We’re seeking proposals to advance metagenomic next generation sequencing (mNGS) technology as a diagnostic tool to counter any infectious disease threat. DRIVe is looking for partners to advance technology development in three areas: - Sequencing hardware that is accurate, portable, and cost-effective - Integrated sample preparation and assay components that improve protocol speed, and efficiency - Bioinformatic analysis tools that are user-friendly, automated, platform-agnostic, and support clinical interpretation This R&D funding opportunity is Area of Interest #26, which is described in amendment 23. Deadline to submit is 12 p.m. ET May 15, 2024. Submit early! Proposals are reviewed on a rolling basis. To learn more: https://ow.ly/fK6K50QCUGu
-
-
There's still time to submit your proposal to the OTA: Strategic Partnership Solicitation and become a D-COHRe Partner! DRIVe is seeking strategic partnerships to bring clinical trial services directly to where patients seek care through enhancing decentralized capabilities for care delivery and clinical studies. The D-COHRe solicitation is open now through June 1, 2024: https://ow.ly/j4Bi50P6xuA
-
The PBC Separator with Selux AST System, from our partner Selux Diagnostics, Inc, is the 87th FDA approval/licensure/clearance for a BARDA-supported product. The PBC Separator allows hospital labs to test directly from a positive blood culture sample using the NGP AST System to determine if bacteria in a patient’s blood sample are susceptible to antibiotics. Because labs will no longer need to subculture these samples, the PBC Separator enables a shorter time-to-result. Clinicians will be able to determine an antibiotic treatment plan more quickly for patients, which can prevent further antibiotic resistance emergence by not exposing bacteria to ineffective antibiotics. This also marks the third BARDA-supported diagnostic product for use with the Selux Next Generation Phenotyping (NGP) AST System, which was previously developed with BARDA support. This milestone demonstrates the value of collaborative public-private partnerships between the U.S. government and product development partners to protect national health security. Learn more: https://ow.ly/ljEK50R5HH7
-
-
Tell a friend—we're moving on March 31! Give us a follow for more updates: https://ow.ly/ElYQ50QYaB2
-
-
Are you interested in partnering with us? Check out our new page for more information about our work: https://ow.ly/qY8X50QX1PZ
-
-
We’re moving on March 31! Give us a follow on our new LinkedIn company page to stay up to date: https://ow.ly/Y1BT50QQz8c
-
-
Have you heard? We’re moving 📦 to a new LinkedIn page. Check it out here ⤵️ https://ow.ly/4vTj50QX0JG
-
-
Tell a friend—we're moving on March 31! Give us a follow for more updates: https://ow.ly/ElYQ50QYaB2
-
-
Are you interested in partnering with us? Check out our new page for more information about our work: https://ow.ly/qY8X50QX1PZ
-